Mitochondria-Containing Microvesicles for Scalable Therapeutic Transfer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to mass-produce mitochondria and preserve them effectively due to their susceptibility to damage outside the intracellular environment, hindering their therapeutic application.
Innovation Solution
A method involving a combination of mitochondrial and extracellular vesicle generation promoting factors to induce cells, particularly mesenchymal stem cells, to produce mitochondria-containing microvesicles, which are encapsulated and protected by small RNA, facilitating large-scale production and preservation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If isolated mitochondria are produced outside the intracellular environment, then mitochondrial preparations can be obtained for therapeutic use, but the mitochondria quickly become damaged and die, making them difficult to preserve
Solution Approach 1:
The patent embeds mitochondria within extracellular vesicles (ECVs), creating a nested structure where mitochondria are protected inside the vesicle membrane. This nesting allows mitochondria to survive outside the intracellular environment by providing them with a protective compartment that maintains their integrity and function during storage and transplantation.
Solution Approach 2:
The patent introduces extracellular vesicles as an intermediary carrier between the intracellular environment and the external therapeutic application. These ECVs act as a mediator that protects mitochondria from damage during isolation, storage, and transplantation, enabling their therapeutic use without direct exposure to harsh external conditions.
2Productivity
If methods for mass-producing mitochondria are developed, then therapeutic potential is enhanced, but the complexity of production and preservation increases
Solution Approach 1:
The patent utilizes the cell's own natural extracellular vesicle secretion machinery to produce and package mitochondria. By stimulating cells to spontaneously release mitochondria-containing ECVs, the system leverages biological self-organization rather than requiring complex artificial production equipment, thereby simplifying the manufacturing process while enabling mass production.
Solution Approach 2:
The patent combines mitochondrial production with extracellular vesicle secretion in a single integrated process. Instead of separately producing mitochondria and then finding a way to preserve them, the method merges these functions by inducing cells to simultaneously produce and package mitochondria into protective vesicles, streamlining the production workflow.
Data Source
AI summary
Provided is a method for promoting generation of a mitochondria-containing microvesicle and a treating method thereof. Specifically, provided is a method for promoting generation of the mitochondria-containing microvesicle with a combination of a mitochondrial generation promoting factor and an extracellular vesicle generation promoting factor. Also provided is a method for generating an extracellular vesicle composition, comprising: co-culturing cells having mitochondria with the mitochondrial generation promoting factor and the extracellular vesicle generation promoting factor to obtain the extracellular vesicle composition rich in the mitochondria-containing microvesicle. Adding the above factors may promote the cells to generate the mitochondria-containing microvesicle. The collected mitochondria are encapsulated by the microvesicle, and therefore can be easily stored and transferred into the cells. Also provided are an isolated extracellular vesicle composition, a pharmaceutical composition comprising the same, and a method for treating diabetes and/or renal injury by administering a medicine comprising the same.